Last reviewed · How we verify
Ad5 CEA Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Ad5 CEA Vaccine (Ad5 CEA Vaccine) — NantCell, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ad5 CEA Vaccine TARGET | Ad5 CEA Vaccine | NantCell, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ad5 CEA Vaccine CI watch — RSS
- Ad5 CEA Vaccine CI watch — Atom
- Ad5 CEA Vaccine CI watch — JSON
- Ad5 CEA Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Ad5 CEA Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ad5-cea-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab